List of Excipients in Branded Drug GENTAMICIN SULFATE

Generic Drugs Containing GENTAMICIN SULFATE

Company	Ingredient	NDC	Excipient
E Fougera & Co a division of Fougera Pharmaceuticals Inc	gentamicin sulfate	0168-0078	METHYLPARABEN
E Fougera & Co a division of Fougera Pharmaceuticals Inc	gentamicin sulfate	0168-0078	PETROLATUM
E Fougera & Co a division of Fougera Pharmaceuticals Inc	gentamicin sulfate	0168-0078	PROPYLPARABEN
Hospira Inc	gentamicin sulfate	0409-1207	EDETATE DISODIUM ANHYDROUS
Hospira Inc	gentamicin sulfate	0409-1207	METHYLPARABEN

What are the Most Frequently-Used Excipients in GENTAMICIN SULFATE?

# Of NDCs	Excipient
37	BENZALKONIUM CHLORIDE
6	BUTYLPARABEN
9	EDETATE DISODIUM
5	EDETATE DISODIUM ANHYDROUS
28	HYDROCHLORIC ACID

Gentamicin Sulfate Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Gentamicin sulfate is an established aminoglycoside with limited core-molecule patent value and a highly competitive generic market. Commercial differentiation is concentrated in excipient selection, container-closure systems, ready-to-use presentation, preservative strategy, stability, and administration convenience. The strongest opportunities are preservative-free ophthalmic products, low-volume ready-to-administer injections, extended-stability presentations, and packaging designed for hospital, outpatient, and global procurement channels.

What is the commercial position of gentamicin sulfate?

Gentamicin sulfate is approved for systemic injection and topical ophthalmic use in the United States. It is used against susceptible aerobic gram-negative organisms and selected gram-positive organisms, although resistance, nephrotoxicity, and ototoxicity restrict its use compared with newer antibiotics.[1][2]

The product is available primarily as:

Dosage form	Main commercial setting	Excipient priorities
Injection	Hospitals, emergency care, inpatient treatment	pH control, tonicity, chemical stability, low particulate burden, container compatibility
Ophthalmic solution	Outpatient ophthalmology and urgent care	Sterility, preservative system, comfort, drop accuracy, multidose stability
Ophthalmic ointment	Eye infections and overnight treatment	Petrolatum-based vehicle, drug uniformity, spreadability, microbiological protection
Topical cream or ointment	Limited human dermatology use; broader veterinary use	Skin tolerability, uniformity, preservative protection, spreadability
Compounded or specialized presentations	Institutional or niche use	Stability, aseptic processing, compatibility, supply reliability

Gentamicin sulfate is a water-soluble sulfate salt. Its commercial value is therefore linked less to active-ingredient discovery and more to reliable delivery, manufacturing economics, and regulatory execution.

What excipients are used in gentamicin sulfate products?

Injectable gentamicin sulfate

Injectable products generally use a simple aqueous formulation. Typical formulation functions include:

• Water for injection as the vehicle.
• Sodium chloride for isotonicity where required.
• pH adjustment with sulfuric acid, sodium hydroxide, or another justified acid-base system.
• A preservative in some multidose presentations.
• Nitrogen or other headspace controls where oxidation or container interaction is a concern.

The exact excipient profile varies by manufacturer and presentation. FDA-approved labels should control development decisions because gentamicin sulfate products are not compositionally identical across suppliers.[1][3]

The injectable formulation should prioritize:

1. Chemical stability through the proposed shelf life.
2. Compatibility with glass vials, plastic containers, elastomeric closures, and infusion systems.
3. Low visible and subvisible particulate levels.
4. Minimal adsorption to tubing and administration components.
5. Compatibility with common hospital diluents.
6. Reduced preparation steps for pharmacy staff.

A preservative-free single-dose vial or ready-to-use bag can command a commercial premium where it reduces compounding work and contamination risk. That opportunity is strongest in emergency, perioperative, neonatal, and outpatient infusion settings.

Ophthalmic solutions

Ophthalmic gentamicin sulfate solutions require a sterility strategy and a multidose-use strategy. Common formulation functions include:

• Borate or phosphate buffering.
• Sodium chloride or another tonicity agent.
• Benzalkonium chloride or an alternative preservative in multidose products.
• Sodium hydroxide or hydrochloric acid for pH adjustment.
• Purified water or water for injection, depending on the manufacturing process.

Benzalkonium chloride can support multidose microbiological protection but may irritate the ocular surface, particularly with frequent dosing or compromised epithelium. A preservative-free unit-dose product can therefore target patients with ocular-surface disease, postoperative use, chronic treatment exposure, or preservative sensitivity.[2][4]

Commercial differentiation can come from:

• Preservative-free unit-dose ampoules.
• Low-irritation preserved multidose bottles.
• Improved drop-size control.
• Low-drip packaging.
• Tamper-evident containers.
• Reduced extractables and leachables.
• Packaging compatible with pediatric or geriatric handling.

Ophthalmic ointments

Ointment products typically use a hydrophobic base such as white petrolatum and mineral oil. The formulation challenge is not solubility but uniform distribution of gentamicin sulfate, microbiological control, ocular comfort, and release from the base.

Potential development improvements include:

• Lower-grit drug dispersion.
• More consistent dose per ribbon length.
• Reduced visual blurring.
• Improved extrusion from the tube.
• Better compatibility with laminated or ophthalmic-grade metal tubes.
• Lower preservative burden.

An ointment may complement, rather than replace, an ophthalmic solution. It can be positioned for nighttime dosing or patients who cannot reliably administer drops.

What formulation patents protect gentamicin sulfate?

The core gentamicin sulfate composition is old and is not generally protected by a meaningful active-ingredient patent estate in the United States. Commercial barriers are more likely to arise from product-specific formulation patents, packaging patents, manufacturing processes, trademarks, and regulatory exclusivity than from the antibiotic molecule itself.

FDA Orange Book patent listings are product-specific. A sponsor must evaluate the exact reference-listed drug, dosage form, strength, and National Drug Code rather than assume that all gentamicin sulfate products have the same patent position.[5]

Potentially protectable subject matter includes:

• Preservative-free multidose ophthalmic systems.
• Novel low-irritation preservative combinations.
• Extended-stability aqueous injections.
• Ready-to-use infusion containers.
• Drug-container closure systems.
• Low-sorption tubing or administration assemblies.
• Controlled drop-size dispensers.
• Manufacturing processes that improve purity or reduce degradation.
• Specific pH and excipient ranges tied to demonstrated stability.
• Combination presentations with compatible diluents or delivery devices.

A formulation patent is more defensible when it claims a defined composition linked to measurable technical performance, such as improved stability, reduced impurity formation, reduced ocular irritation, or reliable delivered dose. Broad claims covering routine use of sodium chloride, buffer, or preservative are vulnerable to validity and obviousness challenges.

When does gentamicin sulfate lose exclusivity?

Gentamicin sulfate has no practical U.S. small-molecule market exclusivity comparable to a newly approved branded drug. The active ingredient has been used clinically for decades, and multiple generic manufacturers supply injectable and ophthalmic products.

Exclusivity category	Gentamicin sulfate position
New chemical entity exclusivity	Expired or not applicable
Orphan-drug exclusivity	Not generally applicable to standard gentamicin sulfate products
Pediatric exclusivity	Product-specific and not generally material to the established market
Core composition patent	No meaningful current protection expected for the old active ingredient
Formulation patent	Possible, but dependent on a specific product and enforceable claims
Regulatory exclusivity for a new presentation	Possible if tied to a qualifying FDA pathway, but not inherent in a generic product
Generic competition	Established

FDA ANDA applicants must address any listed patents for the relevant reference product through the applicable certification pathway, including Paragraph IV certification where appropriate.[5][6]

What is the Orange Book status of gentamicin sulfate?

The Orange Book does not create a single market-wide patent status for gentamicin sulfate. Listings are associated with particular reference products. The relevant analysis requires review of:

• The reference-listed drug.
• Dosage form and strength.
• Current patent listings.
• Pediatric exclusivity codes.
• Generic approval status.
• Therapeutic equivalence evaluations.
• Any withdrawn or delisted reference products.

For an established generic such as gentamicin sulfate, the principal commercial risk usually comes from approval competition, supply interruptions, manufacturing observations, and contracting pressure rather than a late-stage Paragraph IV event.

Which companies are challenging gentamicin sulfate patents?

No company-wide Paragraph IV challenger landscape can be assigned to gentamicin sulfate without identifying a specific reference-listed drug and current Orange Book record. Generic manufacturers have historically supplied gentamicin sulfate products through ANDA pathways, but the existence of a generic product does not establish that it challenged a patent.

The relevant legal questions are product-specific:

1. Was an ANDA filed against an active reference product?
2. Did the applicant submit Paragraph I, II, III, or IV certification?
3. Did the reference sponsor list an enforceable patent?
4. Was litigation filed within the statutory period?
5. Did the FDA impose a 30-month stay?
6. Did the parties settle, and did the agreement include a launch date or license?

A current litigation conclusion should rely on the FDA Orange Book, FDA patent certification records where available, PACER, and district court filings. Generic approval alone does not prove a patent challenge.

How strong is the gentamicin sulfate patent estate?

The patent estate is weak at the molecule level and potentially moderate at the product level.

Patent layer	Relative strength	Commercial assessment
Gentamicin sulfate active ingredient	Low	Mature antibiotic with extensive prior art
Basic aqueous injection	Low	Routine excipients and conventional processing are vulnerable
Preservative-free ophthalmic product	Moderate	Strength depends on technical data and claim specificity
Device and dropper system	Moderate	Can create practical differentiation and substitution friction
Ready-to-use infusion presentation	Moderate	Combination of formulation, container, and use claims may add value
Manufacturing impurity-control process	Moderate to high	Stronger if the process produces reproducible quality advantages
Trademark and packaging	Low to moderate	Commercial protection, not a barrier to generic substitution

A sponsor should avoid relying on a single broad composition patent. A layered strategy combining formulation, container, process, and device claims is more durable.

What formulation opportunities have the highest commercial value?

Preservative-free ophthalmic unit doses

This is the clearest formulation opportunity. Unit-dose packaging removes the need for a multidose preservative system and supports ocular-surface positioning. The tradeoff is higher packaging cost, more units per treatment course, and greater logistics volume.

Ready-to-use injectable products

Premixed or ready-to-administer gentamicin sulfate can reduce pharmacy preparation, dosing errors, and handling requirements. The development program must establish stability in the final container and compatibility with administration sets.

Low-volume presentations

Concentrated presentations can reduce storage and transport requirements. They require careful control of dosing accuracy, dilution instructions, and medication-error risk.

Improved multidose ophthalmic packaging

An optimized bottle can combine preservative protection with lower delivered drop volume. This can improve treatment duration, reduce waste, and support premium positioning without changing the active ingredient.

Hospital procurement formats

Hospitals may value:

• Barcoded unit-dose packaging.
• Latex-free closures.
• Terminally sterilized products where appropriate.
• Small and large vial sizes.
• Standardized concentrations.
• Reliable back-order performance.
• Packaging compatible with automated dispensing systems.

Supply reliability can have greater commercial value than minor formulation differences in a low-cost injectable antibiotic category.

What manufacturing and IP barriers affect gentamicin sulfate?

The main manufacturing barriers are quality and supply-chain related:

• Gentamicin is produced through fermentation, creating batch-to-batch impurity and potency-control requirements.
• Sulfate content and active-component composition require tight analytical control.
• Sterile injectable and ophthalmic manufacturing require validated aseptic or sterilization processes.
• Container-closure integrity is critical for sterile products.
• Extractables and leachables can affect both ophthalmic and injectable presentations.
• Aminoglycoside products require control of degradation products and particulate matter.
• Global supply can be exposed to limited fermentation capacity and active pharmaceutical ingredient concentration.

Manufacturing know-how may be more valuable than a broad formulation patent. A process that improves consistency, reduces impurity burden, or extends shelf life can support regulatory differentiation and licensing.

How does gentamicin sulfate compare with competing antibiotics?

Product	Main advantage	Excipient opportunity	Commercial constraint
Gentamicin sulfate	Low cost, established efficacy, broad generic availability	Preservative-free ophthalmic and ready-to-use injectable products	Resistance and toxicity
Tobramycin	Strong ophthalmic presence and aminoglycoside familiarity	Comfortable multidose and unit-dose ophthalmic systems	Generic competition
Amikacin	Utility against resistant organisms	Ready-to-use injection and hospital packaging	Higher cost and injectable use
Neomycin combinations	Broad topical and ophthalmic combination use	Combination formulations and consumer-friendly delivery	Hypersensitivity and combination-product complexity
Fluoroquinolone ophthalmics	Convenient dosing and broad ophthalmic use	Advanced dropper systems and low-irritation vehicles	Strong competition and mature market

Gentamicin sulfate is most competitive where acquisition cost, established supply, and institutional familiarity outweigh dosing convenience and toxicity concerns.

What regulatory pathway applies to new gentamicin sulfate products?

A conventional equivalent injectable or ophthalmic product will generally be developed through an ANDA if it can meet the applicable pharmaceutical equivalence and bioequivalence requirements. A materially different formulation, delivery system, or therapeutic claim may require a different FDA pathway or additional clinical and usability evidence.[6]

The regulatory strategy should address:

• Active ingredient sameness.
• Strength and dosage form.
• Sterility and particulate requirements.
• Container-closure integrity.
• Preservative effectiveness for multidose products.
• In-use stability.
• Extractables and leachables.
• Ophthalmic irritation and comfort where relevant.
• Compatibility with diluents and administration systems.
• Inactive-ingredient precedent under the FDA Inactive Ingredient Database.[7]

The FDA Inactive Ingredient Database can support excipient selection, but prior use does not eliminate the need to justify concentration, route, dosage form, and product-specific safety.

What licensing and commercial opportunities exist?

Licensing opportunities are most credible in four areas:

1. A differentiated ophthalmic platform with preservative-free or low-irritation delivery.
2. A ready-to-use injectable portfolio with validated extended stability.
3. A specialized container or administration device that reduces waste and dosing error.
4. A manufacturing platform that improves gentamicin sulfate purity, consistency, or supply resilience.

A licensee would likely value regulatory readiness, validated stability data, supply capacity, and hospital contracting access more than a broad composition patent. The target market is primarily generic pharmaceutical companies, specialty ophthalmic manufacturers, hospital-product suppliers, and contract manufacturers with sterile capabilities.

What generic launch risks exist for gentamicin sulfate?

Generic launch risk is high for undifferentiated products because:

• The active ingredient is mature.
• Multiple suppliers may exist.
• Price competition is substantial.
• Substitution is relatively easy for standard presentations.
• Hospital purchasing often favors lowest landed cost and supply continuity.
• Formulation patents may be narrow.
• A new product may need to displace established contracts.

Launch risk is lower for a product with a clear operational advantage, such as a preservative-free unit dose, a premixed injection, or a container system that reduces preparation and administration burden.

What is the geographic coverage of gentamicin sulfate opportunities?

The United States has a mature generic market and emphasizes FDA equivalence, sterile manufacturing, and procurement economics. Europe and other regulated markets require country-specific marketing authorization and may offer opportunities for preservative-free ophthalmic products. Emerging markets may place greater value on low cost, ambient stability, smaller pack sizes, and dependable supply.

A global strategy should avoid assuming that one excipient package is transferable across jurisdictions. Preservative limits, ophthalmic labeling, packaging requirements, and allowable manufacturing changes can differ by region.

Key Takeaways

• Gentamicin sulfate has limited core patent value and established generic competition.
• Excipient strategy should focus on stability, sterility, tolerability, packaging, and administration efficiency.
• Preservative-free ophthalmic unit doses are the strongest differentiated opportunity.
• Ready-to-use injectable products can create value by reducing pharmacy handling.
• Product-level patents may protect formulations, devices, packaging, and manufacturing processes, but broad routine-excipient claims are vulnerable.
• The Orange Book analysis must be tied to a specific reference-listed product.
• Manufacturing consistency and supply reliability may provide greater commercial protection than the active ingredient.
• Generic products face high price pressure unless they solve a clear hospital, ophthalmic, or logistics problem.

FAQs

Can benzalkonium chloride be used in gentamicin sulfate ophthalmic products?

Yes. Benzalkonium chloride is used in some multidose ophthalmic products, but concentration, preservative effectiveness, ocular tolerability, and labeling must be justified for the specific formulation.[2][4]

Is a preservative-free gentamicin sulfate eye drop patentable?

Potentially. Patentability depends on the claimed composition, packaging, stability, delivered dose, and demonstrated technical effect. Preservative removal alone may not support strong claims without unexpected performance or a defined delivery system.

Can gentamicin sulfate be formulated in prefilled syringes?

Potentially, subject to stability, container compatibility, extractables and leachables, sterility, dose accuracy, and device regulations. The syringe materials and closure system may create more development risk than the aqueous formulation.

Does gentamicin sulfate require a biosimilar strategy?

No. Gentamicin sulfate is a chemically defined small-molecule antibiotic, not a biologic. Generic-drug requirements apply rather than biosimilar requirements.

What is the most defensible commercial position for a new gentamicin sulfate product?

A preservative-free ophthalmic unit-dose product or a ready-to-use injectable presentation with validated stability and strong supply reliability offers the clearest differentiation from standard low-cost generics.

References

1. U.S. Food and Drug Administration. (n.d.). Gentamicin sulfate injection prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Gentamicin sulfate ophthalmic solution prescribing information. DailyMed.

3. U.S. Pharmacopeial Convention. (2024). Gentamicin sulfate monograph. United States Pharmacopeia and National Formulary.

4. U.S. Food and Drug Administration. (2017). Ophthalmic drug products for over-the-counter human use: Guidance for industry. FDA.

5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, 45th ed. FDA.

6. U.S. Food and Drug Administration. (2017). ANDAs for certain highly purified synthetic peptides: Guidance for industry. FDA.

7. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.